The Europe antifungal agents market is expected to increaseat a CAGR of 7.10% in the forecasted period of 2017-2025. The market was valued to be $1899 million in 2016 and is expected to surge to $3508 million by 2025. Poor hygiene, developing new drug resistance and initiatives taken by the government in healthcare policies and programs are some of the factors helping the market to move ahead.
The antifungal agent market segmentation by drug types is on the basis of Echinocandins market, Azoles market, Polyenes market, Allylamines, and others. It is further segmented by therapeutic indications on the basis of Aspergillosis, Dermatophytosis and Candidiasis market. It is further divided by applications on the basis of topical antifungal agents and Oral drugs market. Alternate treatment options and regulatory conditions are the restraints faced by the anti-fungal market.
The major market players in the antifungal market are Abbott Laboratories, Arbor PharmaceuticalsINC, Baxter, AstellasPharmaInc, Bayer Healthcare, Teva Pharmaceuticals, Gilead, GlaxoSmithKline, Johnson&Johnson, Kramer Laboratories, Merck Co, Novartis and Pfizer, Sanofi- Aventis, Vertex Pharmaceuticals.